Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p136
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 136/312)
Character Range: 16314261–16324543

The treatment must be used in combination with at least one of: metformin, a sulfonylurea, insulin; AND
                                                                                                                           The condition must be inadequately responsive to at least one of: metformin, a sulfonylurea, insulin.
                                                                                                                           Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor.
C15267              P15267         CN15267          Dapagliflozin with metformin                                           Diabetes mellitus type 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 15267
                                                    Empagliflozin with metformin                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must be inadequately responsive to metformin.
                                                                                                                           Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor.
C15269              C15269         CN15269          Dapagliflozin with sitagliptin                                         Diabetes mellitus type 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 15269
                                                    Empagliflozin with linagliptin                                         The treatment must be in combination with at least metformin; AND
                                                                                                                           The condition must be inadequately responsive to dual therapy consisting of metformin with either: a DDP-4 inhibitor, an SGLT2 inhibitor.
                                                                                                                           Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor, another DPP4 inhibitor.
C15270              C15270         CN15270          Dapagliflozin with sitagliptin                                         Diabetes mellitus type 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 15270
                                                    Empagliflozin with linagliptin                                         The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The treatment must be in combination with at least metformin; AND
                                                                                                                           The condition must be inadequately responsive to dual therapy consisting of metformin with either: a DDP-4 inhibitor, an SGLT2 inhibitor.
                                                                                                                           Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another SGLT2 inhibitor, another DPP4 inhibitor.
C15276              P15276         CN15276          Alogliptin with metformin                                              Diabetes mellitus type 2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 15276
                                                    Linagliptin with metformin                                             The condition must be inadequately responsive to metformin.
                                                    Saxagliptin with metformin                                             Patient must not be undergoing concomitant PBS-subsidised treatment with any of: a GLP-1 receptor agonist, another DPP4 inhibitor.
                                                    Sitagliptin with metformin
                                                    Vildagliptin with metformin
C15281              P15281         CN15281          Osimertinib                                                            Stage IB, II or IIIA non-small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures
                                                                                                                           Adjuvant therapy
                                                                                                                           Patient must be both: (i) initiating treatment, (ii) untreated with EGFR-TKI for non small cell lung cancer; OR
                                                                                                                           Patient must be continuing existing PBS-subsidised treatment with this drug; OR
                                                                                                                           Patient must be both: (i) transitioning from existing non-PBS to PBS-subsidised supply of this drug, (ii) untreated with EGFR-TKI at the time this drug was initiated.
                                                                                                                           The treatment must be for the purpose of adjuvant therapy following surgical resection; AND
                                                                                                                           Patient must have evidence of an activating epidermal growth factor